JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Actinium Pharmaceuticals Inc

Closed

1.77 -2.75

Overview

Share price change

24h

Current

Min

1.77

Max

1.79

Key metrics

By Trading Economics

Income

-9.3M

-16M

Employees

31

EBITDA

-9.3M

-17M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+235.2% upside

Dividends

By Dow Jones

Next Earnings

1 Aug 2025

Market Stats

By TradingEconomics

Market Cap

4.4M

53M

Previous open

4.52

Previous close

1.77

Actinium Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

25 Jul 2025, 17:53 UTC

Major Market Movers

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25 Jul 2025, 15:58 UTC

Earnings
Major Market Movers

Aon Shares Rise After 2Q Earnings Beat

25 Jul 2025, 15:08 UTC

Major Market Movers

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25 Jul 2025, 21:40 UTC

Market Talk

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25 Jul 2025, 21:23 UTC

Market Talk

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25 Jul 2025, 20:40 UTC

Earnings

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 Jul 2025, 20:10 UTC

Earnings

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 Jul 2025, 19:56 UTC

Earnings

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25 Jul 2025, 19:14 UTC

Market Talk

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25 Jul 2025, 19:10 UTC

Market Talk

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25 Jul 2025, 19:01 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 Jul 2025, 18:45 UTC

Market Talk

Gold Ends Down Week on Lower Note -- Market Talk

25 Jul 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

Sale Could Fetch Around $1B, Sources Say -- WSJ

25 Jul 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

LVMH in Talks to Sell Marc Jacobs -- WSJ

25 Jul 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25 Jul 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25 Jul 2025, 17:38 UTC

Major Market Movers

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25 Jul 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Extends Decline -- Market Talk

25 Jul 2025, 17:13 UTC

Earnings

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 Jul 2025, 16:46 UTC

Earnings

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25 Jul 2025, 16:45 UTC

Earnings

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25 Jul 2025, 16:27 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 Jul 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 Jul 2025, 16:02 UTC

Earnings
Acquisitions, Mergers, Takeovers

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25 Jul 2025, 15:34 UTC

Earnings

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25 Jul 2025, 15:06 UTC

Market Talk

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25 Jul 2025, 15:05 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25 Jul 2025, 14:45 UTC

Market Talk

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25 Jul 2025, 14:44 UTC

Market Talk

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25 Jul 2025, 14:36 UTC

Market Talk
Earnings

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Peer Comparison

Price change

Actinium Pharmaceuticals Inc Forecast

Price Target

By TipRanks

235.2% upside

12 Months Forecast

Average 6 USD  235.2%

High 9 USD

Low 4 USD

Based on 3 Wall Street analysts offering 12 month price targets forActinium Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.